عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Twenty Countries Ask EU to Prepare for Climate Change Health Hazards 

A woman stands on the edge of the Garzweiler lignite open cast mine near Luetzerath, western Germany, on November 12, 2022, as in background can be seen wind engines. (AFP)
A woman stands on the edge of the Garzweiler lignite open cast mine near Luetzerath, western Germany, on November 12, 2022, as in background can be seen wind engines. (AFP)
TT
TT

Twenty Countries Ask EU to Prepare for Climate Change Health Hazards 

A woman stands on the edge of the Garzweiler lignite open cast mine near Luetzerath, western Germany, on November 12, 2022, as in background can be seen wind engines. (AFP)
A woman stands on the edge of the Garzweiler lignite open cast mine near Luetzerath, western Germany, on November 12, 2022, as in background can be seen wind engines. (AFP)

A large majority of European Union countries want stronger EU action to prepare for the health consequences of climate change and global warming's potential to spread vector-borne diseases, a document seen by Reuters showed.

Europe is experiencing severe health impacts as a result of the changing climate. Around 61,000 people are estimated to have died in sweltering European heatwaves last summer, suggesting countries' heat preparedness efforts are falling well short.

In a joint paper, 20 of the EU's 27 member countries including Croatia, Germany, Greece, Malta and the Netherlands, have urged the EU to increase its surveillance of the threats to health and healthcare systems posed by extreme weather, to help countries prepare.

The EU should also draft plans for infections of zoonotic and climate-sensitive vector-borne diseases, and strengthen its early warning and response system for if disease-spreading vectors are detected, the countries said.

"Unless proactive measures are taken, it is a matter of time before certain preventable infectious diseases, which are currently more prevalent in other regions, become increasingly common occurrences within the EU," the paper said.

It was also backed by Austria, Belgium, Cyprus, the Czech Republic, Denmark, Estonia, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Portugal, Romania and Slovenia.

Climate change is increasing the risk that infectious diseases will spread into new areas - including in Europe, as summers become hotter and longer, and increased flooding creates favorable conditions for spreading infectious disease.

An example of this is the tiger mosquito, which is now present in 337 regions in Europe - more than double the number a decade ago, said the paper, which was reported earlier on Monday by the Financial Times.

EU countries' health ministers will discuss the paper in a meeting next week. The EU is currently drafting its first climate risk assessment, due to be published next year as a basis for future policies to cope with climate hazards like heatwaves and wildfires.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”